Amphoteric Drugs. I. Synthesis and Antiallergic Activity of (4-(Diphenylmethoxy)piperidino)-, (4-(Diphenylmethyl)piperazinyl)- and (4-(Diphenylmethylene)piperidino)alkanoic Acid Derivatives.
作者:Nobuhiko IWASAKI、Jun SAKAGUCHI、Tetsuo OHASHI、Eiji TAKAHARA、Nobuo OGAWA、Shingo YASUDA、Eiichi KOSHINAKA、Hideo KATO、Yasuo ITO、Hiroyuki SAWANISHI
DOI:10.1248/cpb.42.2276
日期:——
A simple method of transforming classical antihistaminics into nonsedative antiallergic agents with strong effects in rat models is described. Various [4-(diphenylmethoxy)piperidino]- (series A), [4-(diphenylmethyl)piperazinyl]- (series B) and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives (series C) were synthesized and examined for antiallergic activities and effects on the central nervous system (CNS), in comparison with the corresponding N-methyl derivatives (1a-c). N-Alkylcarboxylic acids (5a-c) showed stronger ingibitory effects on compound 48/80-induced lethality in rats than the corresponding N-methyl derivatives (1a-c). In particular, N-alkylcarboxylic acids (5a) in series A exhibited approximately 100-fold stronger inhibitory effects than 1a, and were the least effective in prolonging the sleeping time on hexobarbital-induced anesthesia in mice in all series. As a result of chemical modification in series A, it was found that introduction of a methyl group at the para-position on one benzene ring in the (diphenylmethoxy)piperidine system effectively reduced CNS side-effects without reducing antiallergic activityl. (+)-3-[4-[(4-Methylphenyl)phenylmethoxy]piperidino]propionic acid ((+)-5l), an optically active isomer of 5l, exhibited a stronger antiallergic effect (ED50=0.17mg/kg, p.o.) than ketotifen and terfenadine in the 48h homologous passive cutaneous anaphylaxis (PCA) test, and moreover exhibited no CNS side-effects, such as prolongation of the sleeping time on hexobarbital-induced anesthesia, at an oral dose of 30mg/kg. Compound (+)-5l was thus proved to be a promising candidate as a nonsedative antiallergic agent.
描述了一种将经典抗组胺药物转化为具有强效的非镇静抗过敏剂的简单方法,该方法在大鼠模型中进行了测试。合成并检查了多种[4-(二苯基甲氧基)哌啶](A系列)、[4-(二苯基甲基)哌嗪](B系列)和[4-(二苯基亚甲基)哌啶]酸衍生物(C系列)的抗过敏活性及对中枢神经系统(CNS)的影响,与相应的N-甲基衍生物(1a-c)进行了比较。N-烷基羧酸(5a-c)对化合物48/80诱导的大鼠致死作用显示出比相应的N-甲基衍生物(1a-c)更强的抑制效果。特别是A系列中的N-烷基羧酸(5a)表现出大约100倍于1a的更强抑制效果,并且在所有系列中,对于延长戊巴比妥诱导的麻醉睡眠时间的效果最差。通过对A系列进行化学修饰发现,在(二苯基甲氧基)哌啶体系中,在一个苯环的对位引入甲基可以有效降低CNS副作用,而不减少抗过敏活性。(+) -3-[4-[(4-甲基苯基)苯基甲氧基]哌啶]丙酸((+) -5l),是5l的光学活性异构体,在48小时同源被动皮肤过敏反应(PCA)测试中展现出比酮替芬和特非那定更强的抗过敏效果(ED50 = 0.17 mg/kg,口服),而且在30 mg/kg的口服剂量下没有表现出延长戊巴比妥诱导的麻醉睡眠时间等CNS副作用。因此,化合物(+) -5l被证明是一个有前景的非镇静抗过敏剂候选药物。